TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Main Feed
Today's Market Intel
Stock Reports
AI Research Reports
Top Stocks
AI-Curated Stock Lists
Commentary
Opinionated Stock Takes
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
IPO Calendar
Upcoming Listings
CommunityDashboard
Log inCreate Account
← Back to TickerSpark
▌Earnings Flash·August 3, 2026

Twist Bioscience Corporation (TWST) rises on earnings misses

Twist Bioscience Corporation (TWST) rises after reporting earnings misses, with shares up 5.5% as investors react to the latest quarterly results.

Earnings FlashTWSTHealthcareMedical - Diagnostics & Research
By TickerSpark·August 3, 2026·2 min read
Twist Bioscience Corporation (TWST) rises on earnings misses
▌Key Takeaway
Twist Bioscience Corporation (TWST) reported a mixed quarter, missing EPS at -$0.56 versus estimates of -$0.49333 while beating revenue at $120 million versus $110 million expected. Shares rose 5.51% to $96.59 as investors rewarded the sales beat, but the three-quarter EPS miss streak keeps profitability the key issue for the stock.

Twist Bioscience Corporation (TWST) Earnings Miss, Stock Rises 5.51%

Twist Bioscience Corporation (TWST) missed EPS at -$0.56 versus a -$0.49333 estimate but beat revenue at $0.12B versus $0.11B, while the stock rose 5.51% to $96.59 in regular-session trading.

Key Numbers

  • EPS: -$0.56 actual versus -$0.49333 estimated, a miss.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Revenue: $0.12B actual versus $0.11B estimated, a beat.
  • Stock reaction: TWST rose 5.51% to $96.59 from $91.55 in regular-session trading.
  • Regular-session range: $80.59 to $97.87.
  • Volume: 1,072,112 shares versus a 1,721,169 average.

    • Revenue Beat, Profitability Miss Keep TWST at a Crossroads

    TWST delivered a split result. The revenue beat supports the quarter's sales picture, but the EPS miss shows that revenue did not translate into earnings in line with the estimate. The earnings call deserves close attention to management's explanation for the EPS miss and its plan to turn the $0.12B revenue result into stronger earnings.

    Recent history adds a caution flag. TWST moved from EPS beats in August and November 2025 to misses in February, May, and August 2026. That three-quarter miss streak makes the -$0.56 result more than a one-quarter blemish. The stock still gained 5.51%, suggesting traders favored the revenue beat over the earnings shortfall, though the move came on below-average volume.

    Get AI research on any stock

    Instant reports, daily intelligence, and an AI analyst in your pocket.

    Get Started →

    Bottom Line

    TWST's revenue beat won the day's vote, but the three-quarter EPS miss streak keeps profitability as the decisive test for the stock.

    Read the full TWST research report
    ▌Common Questions

    Frequently asked questions

    +Why did Twist Bioscience stock rise after missing earnings?
    Twist Bioscience (TWST) rose 5.51% because investors focused on the revenue beat, with sales coming in at $0.12 billion versus $0.11 billion expected. The market appeared to look past the EPS miss at -$0.56, at least for the session.
    +Did Twist Bioscience beat revenue in its latest quarter?
    Yes. Twist Bioscience reported revenue of $0.12 billion, above the $0.11 billion analyst estimate. That top-line beat helped support the stock despite weaker-than-expected earnings.
    +How badly did Twist Bioscience miss EPS?
    Twist Bioscience posted EPS of -$0.56, compared with an estimated -$0.49333. The miss shows that revenue growth did not translate into earnings as well as analysts expected.
    +What does Twist Bioscience's latest earnings report mean for investors?
    The report suggests demand remains solid, but profitability is still the main concern for Twist Bioscience (TWST). With three straight quarterly EPS misses, investors will likely want clearer evidence that revenue growth can convert into better earnings.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on TWST?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the TWST report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full TWST research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the TWST report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on TWST

    More to read

    All articles
    Twist Bioscience Corporation (TWST) rises on deep earnings analysis
    TWST

    Twist Bioscience Corporation (TWST) rises on deep earnings analysis

    Twist Bioscience Corporation (TWST) rose after a mixed quarter that featured an EPS miss but a revenue beat, continued sequential growth, and improving segment momentum. This deep dive examines the margin expansion, adjusted EBITDA breakeven path, and why investors focused on the bigger operating picture.

    Aug 3·7 min
    Twist Bioscience (TWST): Growth Engine, But Valuation Is Rich
    TWST

    Twist Bioscience (TWST): Growth Engine, But Valuation Is Rich

    Twist Bioscience posted 19.3% revenue growth in fiscal Q2 2026 and raised full-year guidance, but it still faces losses and a demanding valuation. The stock earns a Hold as execution improves while investors wait for profitability.

    Aug 3·22 min
    Twist Bioscience Corporation (TWST) drops after deep earnings miss
    TWST

    Twist Bioscience Corporation (TWST) drops after deep earnings miss

    Twist Bioscience Corporation (TWST) drops despite revenue growth and raised guidance, as a wider-than-expected EPS loss overshadowed strong segment momentum, margin improvement, and continued sequential sales gains. This deep-dive breaks down the earnings miss, operating trends, and why investors focused on profitability over the top-line beat.

    May 5·10 min